This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceutical companies communicate, visit and engage with physicians. The threat of disease spread and other risk factors from COVID-19 have only compounded this. How engagement with HCPs will evolve in the future.
Just as the wider healthcare system continues to acclimate to a new normal, the way pharma and physicians communicate is experiencing a technological revolution. Physician access issues coupled with message delivery disconnects only compounded the problem. Inefficient communications pre-COVID.
Some takeaways on those efforts that we gleaned from the report: Compounding. OC devoted a lot of resources to its compliance efforts directed at human drug compounding. Communication in this area included on-line videos, webinars, summits, conferences, and international outreach. Drug Supply Chain.
Implementation of GFI #256 Earlier this year, the FDA finalized regulatory guidance for compounded medications, known as GFI #256. If GFI is affecting your practice’s ability to get compounded medications for office use, partnering with a trusted 503B outsourcing facility can help you eliminate risks of limited ordering.
This education can be delivered through various formats, such as webinars, videos, and written materials. Utilize digital tools Digital engagement tools, such as patient portals and mobile applications , can facilitate direct communication between patients and healthcare providers.
We asked her to share her expertise on the importance of a robust inventory management system and best practices for finding a pharmacy partner, ordering and restocking, and care team communication. I think that a lot of times, practices look at compounded meds and consider them regular pharmaceuticals.
Engaging these communities in the policy development process ensures that their voices are heard and that their unique perspectives are incorporated into policy decisions. When combined with the challenges of living with a disability, these individuals may encounter compounded discrimination and systemic biases.
Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound. How does bioavailability play a role in biopharmaceutics? Now fraction absorbed and bioavailability are often confused and used interchangeably.
When it comes to highly sensitive large-molecule drugs, sourcing premium elastomeric components with a cleaner compound, such as Datwyler’s FM457, is an essential step in reducing the E&L risk. This on-demand webinar discusses the importance of a patient-appropriate BL & GF profile.
From alcohols to quaternary ammonium compounds, each type of agent has a unique mode of action, with varying degrees of efficacy. It is also essential to evaluate the reliability of the company supplying the ingredient: do they provide sufficient communication and documentation? There are many other aspects to take into consideration.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content